Healthcare stock Perrigo (NYSE: PRGO) reported a 3.1% year-over-year decline in core sales and a nearly 21% drop in core earnings to $0.46 per share for Q2 2026. The company's CEO also abruptly left in early June. Analysts warn that despite the high dividend yield, the weak financial performance, shrinking business, and leadership uncertainty pose significant risks, potentially leading to a dividend cut.